Press Release Details

Cerus Corporation Announces Proposed Stock Offering

February, 11 1999

CONCORD, Calif., Feb. 11 /PRNewswire/ -- Cerus Corporation (Nasdaq: CERS) announced today that it has filed a registration statement with the Securities and Exchange Commission relating to the proposed public offering of 2,000,000 shares of common stock. All shares are to be sold by Cerus. Cerus has granted the underwriters an option to purchase an additional 300,000 shares solely to cover over-allotments, if any. The managing underwriters for the offering are Morgan Stanley & Co. Incorporated, BT Alex. Brown, Incorporated and SG Cowen Securities Corporation.

Cerus expects to use the net proceeds of the offering to fund research and development, including clinical trials, and for general and administrative expenses, capital expenditures and working capital.

A registration statement relating to these securities has been filed with the Securities and Exchange Commission but has not yet become effective. These securities may not be sold nor may offers to buy be accepted prior to the time the registration statement becomes effective. This press release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of these securities in any state in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state.

When available, a preliminary prospectus may be obtained from Morgan Stanley & Co. Incorporated, 1585 Broadway, New York, NY 10036, Attention: Prospectus Department, BT Alex. Brown, Incorporated, One South Street, Baltimore, MD 21202, Attention: Prospectus Department and SG Cowen Securities Corporation, Four Embarcadero Center, Suite 1200, San Francisco, CA 94111, Attention: Prospectus Department.

Cerus Corporation is developing systems designed to enhance the safety of blood transfusions by inactivating pathogens in blood components (platelets, plasma and red blood cells used for transfusion) and by inactivating white blood cells, which are responsible for a variety of adverse transfusion reactions. The company's platform technologies, which prevent viral, bacterial and cellular replication, may have potential applications in the health care field beyond pathogen inactivation in blood components.

Cerus Corporation is collaborating with the Fenwal Division of Baxter Healthcare Corporation to develop, manufacture and market pathogen inactivation systems for blood components used for transfusion. Baxter, a global medical products and services company, focuses on critical therapies for life-threatening conditions. Baxter is a leader in technologies related to blood and the circulatory system. The Fenwal Division develops, manufactures and markets products and services for the collection, separation, storage and transfusion of blood and its components.

This news release contains forward-looking statements that involve risks and uncertainties. Actual results could differ materially from the above forward-looking statements as a result of certain factors, including the uncertainty of the timing and results of any trials, regulations by the FDA, the uncertainty of replication of animal data in humans, the uncertainty of market acceptance of any products, competitive conditions, the uncertainty of future financing and other factors discussed in the company's 1997 Annual Report on Form 10-K.

    Global Headquarters

  • 1220 Concord Avenue
  • Concord, CA US 94520
  • +1 925.288.6000

    European Headquarters

  • Stationsstraat 79-D
  • 3811 MH Amersfoort, Netherlands
  • +31 (0) 33 49 60 600